# OnCo record herizon-gea-01 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/herizon-gea-01/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "herizon-gea-01", "NCT05152147" ;
  schema:name "HERIZON-GEA-01"@en ;
  schema:description "A two-armed HER2 antibody beat Herceptin head-to-head as first-line treatment for HER2-positive stomach cancer, the first such win since 2010."@en ;
  schema:url <https://onco.cc/trials/herizon-gea-01/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05152147>, <https://ascopubs.org/doi/10.1200/JCO.2026.44.2_suppl.LBA285> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2021-12-02" ;
  onco:cancers <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/esophageal/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/tislelizumab/> ;
  onco:companies <https://onco.cc/companies/jazz/>, <https://onco.cc/companies/beone/> .